May 01, 2020
An arbitrator has concluded that a dispute between Daiichi Sankyo Co. Ltd. and a U.S. biotechnology company over cancer drug patents should be arbitrated, saying he was obligated to do so since it was not obvious whether the dispute fell under an exclusion in the parties' agreement.
April 09, 2020
Daiichi Sankyo Co. Ltd. told a Delaware court Wednesday that it must decide whether its dispute with a U.S. biotechnology company over cancer drug patents must be arbitrated or litigated, saying a magistrate judge created a "new bright-line rule" when she recommended referring the matter to an arbitrator.
March 16, 2020
An arbitrator weighing whether he can adjudicate biotechnology company Seattle Genetics Inc.'s dispute with Daiichi Sankyo Co. Ltd. over cancer drug patents will wait for recommendations from a Delaware court before deciding, according to the Japanese pharmaceutical company.